Stock Transfers After Hours:
Epizyme, Inc. (Nasdaq: EPZM) 24.2% LOW; announced that it intends to offer and sell shares of its common stock in an underwritten public offer. Epizyme also aims to give underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the common stock shares offered on offer. All parts in the proposed offering will be sold by Epizyme.
LendingClub (NYSE: LC) 10.8% LOW; reported Q4 EPS of $ 0.27, $ 0.05 better than the analyst’s estimate of $ 0.22. Revenue for the quarter reached $ 262.2 million compared to the consensus estimate of $ 245.8 million. LendingClub sees revenue in Q1 2022 of $ 255-265 million, compared to the consensus of $ 257 million. LendingClub sees FY2022 revenue of $ 1.1-1.2 billion, compared to the consensus of $ 1.16 billion.
ServiceNow (NYSE: NOW) 10.5% HIGH; reported Q4 EPS of $ 1.46, $ 0.03 better than the analyst’s estimate of $ 1.43. Revenue for the quarter reached $ 1.61 billion compared to the consensus estimate of $ 1.6 billion. Q1 Subscription revenues are seen at $ 1.61- $ 1.615 billion. Subscription revenues in FY22 are seen as $ 7.02- $ 7.04 billion.
Zymeworks Inc. (NYSE: ZYME) 9.6% LOW; announced that it had initiated an underwritten public offering of its common shares and, in exchange for common shares to certain investors, pre-funded warrants to purchase its common shares.
Qualtrics International (NASDAQ: XM) 9.3% HIGH; reported Q4 EPS of ($ 0.07), $ 0.05 worse than the analyst’s estimate of ($ 0.02). Revenue for the quarter reached $ 316 million compared to the consensus estimate of $ 297.61 million.
Galapagos NV (NASDAQ: GLPG) 7.5% HIGH; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels has an impressive track record of success in innovative drug discovery and development, and extensive experience in biotech and pharma, across a range of roles and therapeutic areas.
Flex Ltd. (NASDAQ: FLEX) 6% HIGH; reported Q3 EPS of $ 0.50, $ 0.13 better than the analyst’s estimate of $ 0.37. Revenue for the quarter reached $ 6.6 billion compared to the agreed -upon estimate of $ 5.6 billion. Flex Ltd. sees. the Q4 2022 EPS of $ 0.41- $ 0.46, compared to the consensus of $ 0.39. Flex Ltd. sees. revenue in Q4 2022 of $ 6.2-6.6 billion, compared to the consensus of $ 5.68 billion. Flex Ltd. sees. the FY2022 EPS of $ 1.85- $ 1.90, compared to the consensus of $ 1.58. Flex Ltd. sees. revenue in FY2022 of $ 25.4-25.8 billion, compared to the consensus of $ 22.34 billion.
Levi (NYSE: LEVI) 5.8% HIGH; reported Q4 EPS of $ 0.41, $ 0.01 better than the analyst’s estimate of $ 0.40. Revenue for the quarter reached $ 1.7 billion compared to the agreed -upon estimate of $ 1.68 billion. Levi saw FY2022 EPS of $ 1.50- $ 1.56, compared to the consensus of $ 1.53. Levi saw revenue in FY2022 of $ 6.4-6.5 billion, compared to the agreed $ 6.38 billion.
Lam Research (NASDAQ: LRCX) 5.8% LOW; reported Q4 EPS of $ 8.53, $ 0.02 better than the analyst’s estimate of $ 8.51. Revenue for the quarter reached $ 4.23 billion compared to the agreed -upon estimate of $ 4.41 billion. Lam Research sees Q1 2023 EPS of $ 7.45 in the middle, compared to the consensus of $ 8.72. Lam Research sees Q1 2023 revenue of $ 4.25 billion in the middle, compared to the consensus of $ 4.49 billion.
Edwards Lifesciences (NYSE: EW) 5% LOW; reported Q4 EPS of $ 0.51, $ 0.04 worse than the analyst’s estimate of $ 0.55. Revenue for the quarter reached $ 1.33 billion compared to the consensus estimate of $ 1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $ 0.54- $ 0.62, compared to the consensus of $ 0.60. Edwards Lifesciences sees revenue in Q1 2022 of $ 1.27-1.35 billion, compared to the agreed $ 1.36 billion. Edwards Lifesciences saw FY2022 EPS of $ 2.50- $ 2.65, compared to the consensus of $ 2.58. Edwards Lifesciences saw revenue in FY2022 of $ 5.5-6 billion, compared to the agreed $ 5.82 billion.
Centene (NYSE: CNC) 5% HIGH; placed an interest in acquiring from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.
Netflix (NASDAQ: NFLX) 4.5% HIGH; Bill Ackman said his Pershing Square hedge fund bought more than 3.1 million shares of Netflix following the recent stock slide. This makes the company a top 20 holder.
Intel (NASDAQ: INTC) 2.6% LOW; reported Q4 EPS of $ 1.09, $ 0.19 which is better than the analyst’s estimate of $ 0.90. Revenue for the quarter reached $ 20.5 billion compared to the consensus estimate of $ 18.32 billion. Intel sees Q1 2022 EPS of $ 0.80, compared to the consensus of $ 0.86. Intel sees revenue in Q1 2022 of $ 18.3 billion, compared to the consensus of $ 17.62 billion.
Tesla (NASDAQ: TSLA) 1.2% HIGH; reported Q4 EPS of $ 2.54, $ 0.28 which is better than the analyst’s estimate of $ 2.26. Revenue for the quarter reached $ 17.72 billion compared to the consensus estimate of $ 16.35 billion.